Day: October 19, 2022

The enhanced Cellebrite investigative evidence management solution further accelerates time to evidence, reduces backlogs, and empowers agencies to utilize resources more efficiently

PETAH TIKVA, Israel and TYSONS CORNER, Va., Oct. 19, 2022 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced the release of the next generation of Cellebrite Guardian, which provides quicker time to evidence (TTE) as it loads evidence within just seconds of receipt and further simplifies workflows to accelerate time to justice.

The latest enhancements create increased flexibility for law enforcement and help them secure privacy as they are able to harness the power of the solution to simplify and streamline end-to-end processes and key pain points in the investigative workflow, including physical duplication, transportation of evidence, and time-consuming evidence review.

We expect Cellebrite Guardian will accelerate TTE by more than 5 times compared to traditional methods¹, enabling agencies to go from collection to collaboration in 2 hours (total time spent on case) compared to the current average TTE of 11 hours. Cellebrite Guardian also allows agencies to use their resources more efficiently.

Without the restraints of limited duration of storage and access to extractions, Cellebrite Guardian puts the customer at the center, allowing them to better address numerous evidence management challenges no matter how big the case or how long it takes.

Upper Allen Township Police Department Lieutenant Brian Barnes stated, “One person solving the case just isn’t the reality anymore. Modern investigations require team members from multiple disciplines, effectively collaborating, to bring justice to a victim. Often these cases involve digital evidence. Cellebrite Guardian is not only managing the critical relationship between investigator and examiner, but also ensuring that digital intelligence is immediately actionable regardless of hardware or skillset. Investigators reviewing phone extractions in a web browser, and quickly providing access to prosecutors via the cloud for instant review, forever changes the inefficient paradigm of yesterday.”

“The faster review capabilities for Cellebrite Guardian are critical for accelerating the time to justice in any investigation,” said Todd Bailey, Vice President and Head of Investigation and Evidence Management Solutions at Cellebrite. “Previously, Guardian had transformed hours of manual review processes into minutes. With our latest release, we have sped up those minutes into mere seconds. This speed, in combination with Guardian’s inbuilt flexibility, enables any agency to resolve cases faster.”

To learn more about Cellebrite Guardian, visit here.

About Cellebrite

Cellebrite’s (NASDAQ: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.

Caution Regarding Forward Looking Statements
This document includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward looking statements include estimated financial information. Such forward looking statements with respect to revenues, earnings, performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the acceptance of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; uncertainties regarding the impact of macroeconomic and/or global conditions, including COVID-19 and military actions involving Russia and Ukraine; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; political and reputational factors related to Cellebrite’s business or operations; risks relating to estimates of market opportunity and forecasts of market growth; Cellebrite’s ability to properly manage its growth; risks associated with Cellebrite’s credit facilities and liquidity; Cellebrite’s reliance on third-party suppliers for certain components, products, or services; challenges associated with large transactions and long sales cycle; risks that Cellebrite’s customers may fail to honor contractual or payment obligations; risks associated with a significant amount of Cellebrite’s business coming from government customers around the world; risks related to Cellebrite’s intellectual property; security vulnerabilities or defects, including cyber-attacks, information technology system breaches, failures or disruptions; the mishandling or perceived mishandling of sensitive or confidential information; the complex and changing regulatory environments relating to Cellebrite’s operations and solutions; the regulatory constraints to which we are subject; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on form 20-F filed with the SEC on March 29, 2022 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Cellebrite Media 
Victor Cooper
Public Relations and Corporate Communications Director
Victor.Cooper@cellebrite.com
+1 404.804.5910

Investors
Investor Relations
investors@cellebrite.com

¹ Research findings 2022, Cellebrite in co-operation with anonymous mid-sized US agency

Leading experts will shed light on topics in the QA space that are close to their hearts

San Francisco, Oct. 19, 2022 (GLOBE NEWSWIRE) — LambdaTest, the leading continuous quality testing cloud platform, announced the launch of Voices of Community, a monthly talk with testing and QA experts from across the globe.

The once-in-a-month free live webinar is hosted by Manoj Kumar, VP – Developer Relations, LambdaTest. Through Voices of Community, the organization hopes to bring experts together to talk about the lessons from the past, discuss the present scenario, and talk about where the industry is headed.

“The community is at the center of everything we do at LambdaTest. Voices of Community will bring community experts to talk on topics that they hold close to their hearts. These are people who have built the platforms and tools we use day in and day out at our jobs. We can’t wait for the community to soak in all the learning,” said Manoj Kumar. Manoj is also a member of the project leadership committee for Selenium and an Appium committer.

In the first episode of Voices of Community, John Ferguson Smart, the author of the best-seller, BDD in Action, as well as Jenkins: The Definitive Guide and Java Power Tools and the creator of the Serenity BDD test automation framework joined Manoj. In the upcoming episode, the renowned testing icon and creator of Selenium WebDriver, Simon Stewart, will be joining in as the guest speaker.

“One thing that I learnt while working on Selenium is that community is the biggest factor for a project’s success. More importantly, I learnt that community is also one of the biggest factors for personal success. Being able to listen and learn from other people’s experience, applying lessons from their insights, learning about what works and what doesn’t, and finding out about the trends in our industry helps us grow as developers and testers. That’s why I’m excited to be part of “Voices of Community” by LambdaTest. I hope that you enjoy and learn from what this initiative will offer the testing community. Wishing them — and you! — every success and the best of luck! Onwards and upwards!,” said Simon Stewart, Creator, Selenium WebDriver.

“The testing and developer landscape is always in a state of flux. Being a QA in today’s digital-led world means that one has to reinvent themselves constantly. The community plays a vital role as people from different walks of life can influence and nudge you to stay constantly updated. Voices of Community by LambdaTest is a great initiative that will bring experts from within the community to share the lessons from the past, discuss the present scenario, and talk about where the industry is headed,” said John Ferguson Smart, Creator, BDD Serenity.

To explore more about the Voices of Community, visit here and to register for the upcoming session with Simon Stewart, visit here.

About LambdaTest

LambdaTest is the leading continuous quality testing cloud platform that helps developers and testers ship code faster. Over 10,000+ customers, one million users across 130+ countries rely on LambdaTest for their testing needs.

LambdaTest platform provides secure, scalable, and insightful test orchestration for
customers at different points in their DevOps (CI/CD) lifecycle:-

● Browser & App Testing Cloud allows users to run both manual and
automated tests of web and mobile apps across 3000+ different browsers,
real devices, and operating system environments.

● HyperExecute helps customers run and orchestrate test grids in the cloud
for any platform and programming language at blazing-fast speeds to cut
down on quality test time, helping developers build software faster. 

For further information please contact the LambdaTest press office: Bilal Mahmood on press@lambdatest.com or +44 (0) 20 3640 7759 and +44 (0) 771 400 7257.

Call for a WHO Resolution to kick-start necessary action

CAPE TOWN, South Africa, Oct. 19, 2022 (GLOBE NEWSWIRE) — The Global Self-Care Federation (GSCF) has today launched the second edition of the Self-Care Readiness Index, examining how self-care policies are being implemented across the world. The first and second editions of the Index, together covering 20 countries, demonstrate very clearly that there is a widespread lack of a coherent view of self-care and its benefits.

Malebona Precious Matsoso,  Former Director General of the Department of Health, South Africa said: “Taking collective action to integrate self-care into the global healthcare continuum is the logical and critical next step as we move to re-evaluate the status of our healthcare systems. To support this, there needs to be a global compact on self-care at the international level, this will provide a frame for national-level policymakers to operate within.”

The Self-Care Readiness Index (SCRI) is a research and policymaking tool which explores the key enablers of self-care in support of designing a better model for healthcare systems. It evaluates countries based on four self-care enablers, supported by measurable indicators of self-care readiness. The four enablers are stakeholder support and adoption; consumer and patient empowerment; comprehensive self-care health policies; and the appropriate regulatory environment.

Manoj Raghunandanan, Chair Elect at the Global Self-Care Federation said, “Self-care is a simple concept but it is not easy. It takes a concerted effort by governments, healthcare professionals, academia, industry, and ultimately, the population at large. But the potential rewards are high: better patient outcomes, more efficient healthcare systems and improved access to care.”

Raghunandanan continued, “This research is clear: self-care is highly effective and efficient. In developed countries, empowering people to care for their own health reduces pressure on healthcare systems. And it is critical for low- and middle-income countries, where self-care can be an incredibly important tool for delivering the goal of universal health coverage, and may actually be the only healthcare option available.”

The second edition of the SCRI covered Australia, Canada, Colombia, Germany, India, Indonesia, Kenya, Mexico, Singapore and the United Arab Emirates. This complemented the countries covered in the first edition: Brazil, China, Egypt, France, Nigeria, Poland, South Africa, Thailand, the United Kingdom and the United States.

Judy Stenmark, Director General at GSCF continued, “Self-care has to be a political priority for every single government across the world. And we are calling on WHO to urgently adopt a Resolution to support the synchronisation of self-care policies to create the momentum for this much-needed change.”

The new SCRI is available here. It is a wide-ranging and comprehensive report, covering in detail the four enablers and the extent of self-care penetration in each of the 10 countries. It is the result of thorough research into each country’s healthcare system, led by GSCF and in collaboration with the World Health Organization’s Traditional, Complementary, and Integrative Medicines and Integrated Health Services Unit, with the support of the eminent healthcare professionals who made up the Expert Advisory Committee.

Contact Information:
Catherine Laverty
claverty@selfcarefederation.org

This content was issued through the press release distribution service at Newswire.com.

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first–in–class precision medicines

• Financing led by M Ventures alongside other new investors JJDC, Pfizer Ventures and British Patient Capital, and including founding investor Oxford Science Enterprises
• Nucleome’s pioneering platform seeks to identify direct genetic linkages to disease-associated genes for drug discovery
• Funds will advance Nucleome’s autoimmune disease programmes and fuel expansion of its dark genome atlas

Oxford, UK, 19 October 2022 – Nucleome Therapeutics Limited, (‘Nucleome’ or ‘the Company’), a biotechnology company decoding the dark matter of the human genome to discover first-in-class precision medicines, today announces it has closed an oversubscribed £37.5 million Series A financing round. The funds will be used to advance the Company’s autoimmune disease programmes, fuel expansion of its dark genome atlas and further develop its pioneering platform.

The financing was led by new investor M Ventures, the strategic, corporate venture capital arm of Merck KGaA, with participation from Johnson and Johnson Innovation-JJDC, Inc. (“JJDC”), the strategic venture capital arm of Johnson & Johnson; Pfizer Ventures, the venture group of Pfizer; British Patient Capital, through its Future Fund: Breakthrough programme; and founding investor Oxford Science Enterprises.

Nucleome has the unique ability to discover and validate first-in-class targets through genetics, by investigating the ‘dark’ region of the human genome, which does not encode for proteins but contains 90% of disease-associated genetic changes. Understanding the role of these genetic variants has been a long-standing challenge, hindering the translation of the human genome into useful drug discovery insights.

Nucleome’s breakthrough platform combines pioneering 3D genome technology and machine learning to shed light on these variants by directly linking genes to diseases and mapping pathways with unprecedented precision for drug discovery.

“We have already made significant progress by mapping genes to genetics in a number of human immune cell types and discovering the first wave of potential first-in-class autoimmune disease targets,” said Dr Danuta Jeziorska, Chief Executive Officer and Co-founder of Nucleome Therapeutics.  “The completion of this oversubscribed round with such a high-calibre group of global life science investors is a recognition of the significance of Nucleome’s platform and its potential to support the development of an exciting portfolio of first-in-class targets for autoimmune diseases.”

Dr Bauke Anninga, Principal at M Ventures, commented: “Nucleome’s differentiated platform technology has the potential to fundamentally shift the way we discover and develop precision medicines. Unlocking the value of the largely unexplored territory of the genome can lead to the identification of high-value drug targets. Nucleome’s platform adds 3D genomic information to a wealth of available genomic data, uncovering a new dimension of information that is disease as well as cell type-specific. We are excited to lead this financing, and alongside our co-investors, partner with Nucleome’s exceptional team to advance their target and drug discovery programmes to bring transformative treatments to patients.”

Dr Jonathan Hepple, Non-executive Director at Nucleome and Advisor to Oxford Science Enterprises, added: “Since its founding in 2019, Nucleome has advanced to become a leader in 3D genomics analysis. Publications in high-impact journals have validated its groundbreaking technology and ability to identify new drug targets where other technologies fall short. With a highly experienced team, this fundraising, backed by an impressive syndicate of world-class investors, will allow Nucleome to explore the dark genome and develop its exciting pipeline of potential drug targets. Oxford Science Enterprises is proud to have supported the Company since its inception and continues to do so, and we look forward to working with the team through this exciting time of growth.”

– Ends –

For more information, please contact:

Nucleome Therapeutics
Dr Danuta Jeziorska, Chief Executive Officer & Founder
contact@nucleome.com

Consilium Strategic Communications
Mary-Jane Elliott/Sukaina Virji/Stella Lempidaki
Nucleome@consilium-comms.com

About Nucleome Therapeutics
Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 90% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. The Company has the unique ability to link these variants to gene function and precisely map disease pathways. Nucleome’s cell type-specific platform creates high resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types, enabling the discovery and development of novel, better and safer drugs. The initial focus of the company is on lymphocytes and related autoimmune disease. Nucleome’s ambition is to build a robust pipeline of drug assets, with corresponding biomarkers. Nucleome Therapeutics was founded by leading experts in gene regulation from the University of Oxford. For more information, please visit www.nucleome.com.

About M Ventures
M Ventures is the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. From its headquarters in the Netherlands and offices in Germany, USA and Israel, M Ventures invests globally in transformational ideas driven by innovative entrepreneurs. Taking an active role in its portfolio companies, M Ventures teams up with management teams and co-investors to translate scientific discoveries into commercial success. M Ventures focuses on identifying and financing novel solutions to some of the most difficult challenges, through company creation and equity investments in fields that will impact the vitality and sustainability of Merck KGaA, Darmstadt, Germany ‘s current and future businesses. For more information, visit www.m-ventures.com.

About Pfizer Ventures
Pfizer Ventures, the venture capital arm of Pfizer Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. Pfizer Ventures seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of our industry.

About British Patient Capital

British Patient Capital is the trading name of British Patient Capital Limited, a wholly-owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank. It forms part of the British Business Bank’s plc’s commercial arm. Its mission is to enable long-term investment in innovative firms led by ambitious entrepreneurs who want to build large scale businesses. Launched in June 2018, British Patient Capital has £2.5bn to invest over 10 years in venture and venture growth capital to support high growth potential innovative UK businesses in accessing the long-term financing they require to scale up. Find out more at britishpatientcapital.co.uk.

About Oxford Science Enterprises
Oxford Science Enterprises (OSE) is an independent, billion-pound investment company, created in 2015 to found, fund and build transformational businesses via its unique partnership with the University of Oxford, the world’s #1 research university.
This partnership enables OSE to work with the brightest academic minds tackling the world’s toughest challenges and guarantees unrivalled access to their scientific research.
In collaboration with its global network of entrepreneurs and advisers, OSE shapes and nurtures complex ideas into successful businesses, while targeting attractive returns for shareholders.
Actively focused on a core portfolio of around 40 companies spanning three high-growth, high-impact sectors – Life Sciences, Health Tech, and Deep Tech – the company adopts a flexible, long-term investment approach, recognising the path from ground-breaking research to global markets takes time and resilience.
To date, OSE has invested £0.5 billion in over 80 ambitious companies built on Oxford science.
A key player in Oxford’s entrepreneurial ecosystem, OSE is highly motivated to foster an environment that catalyses pioneering research and steers it to commercial success.
Find out more: oxfordscienceenterprises.com | Twitter | LinkedIn

Triller ร่วมมือกับ Epik และศิลปินรายใหญ่ที่สุดในวงการบันเทิงเพื่อสร้างแพลตฟอร์มดนตรีเสมือนจริง เกม กีฬา และการแสดงสดแบบครบวงจรแห่งแรกของโลก

ลิงก์ไปยังตัวอย่างวิดีโอของ Metaverz ดูได้ที่นี่

LOS ANGELES, Oct. 19, 2022 (GLOBE NEWSWIRE) — Triller ซึ่งเป็นแพลตฟอร์มครีเอเตอร์ชั้นนำที่ขับเคลื่อนด้วย AI กำลังใช้แนวทางที่เน้นความสำคัญให้ครีเอเตอร์เป็นอันดับหนึ่งในเมตาเวิร์ส ในวันนี้ Triller ได้ประกาศการลงทุนล่าสุดของทางบริษัท ซึ่งได้แก่ Metaverz แพลตฟอร์มดิจิทัล เทคโนโลยี สื่อ และความบันเทิงเสมือนจริงแบบครบวงจรแห่งแรก โดยภายใน Metaverz นั้น แฟน ๆ จะสามารถเข้าร่วมคอนเสิร์ตเสมือนจริงที่มีศิลปินคนโปรดของแฟน ๆ แสดงอยู่ หรือเดินผ่านเชือกกำมะหยี่ของไนท์คลับเสมือนจริง และเข้าไปในห้องวีไอพีเพื่อโต้ตอบกับคนดัง อินฟลูเอนเซอร์ และครีเอเตอร์ได้

“ทางเรารู้สึกตื่นเต้นเป็นอย่างยิ่งที่จะเปิดตัว Metaverz และเปิดการเข้าถึงโดยตรงให้กับครีเอเตอร์จากทั่วทุกมุมโลกครับ” Mahi de Silva ซีอีโอของ Triller กล่าว “ทางเรามุ่งมั่นที่จะขยายบริการต่าง ๆ ที่เรามีต่อผู้ใช้ ครีเอเตอร์ และธุรกิจของเรา และเข้าสู่เมตาเวิร์สอย่างมีกลยุทธ์ ซึ่งจะทำให้ Triller อยู่ในแนวหน้าของเทรนด์ที่น่าสนใจหลายอย่าง ซึ่งรวมถึง Web3 และการกระจายอำนาจ ตอนนี้เราอยู่ในแนวหน้าของอนาคตของเนื้อหาสำหรับครีเอเตอร์ ตั้งแต่ของสะสมและของที่ระลึกที่ได้รับการสนับสนุนจาก NFT ไปจนถึงคอนเสิร์ตเสมือนจริง การเล่นเกมและการจับจ่าย ระบบนิเวศน์ Metaverz จะฉีกแนวออกไปเลยล่ะครับ”

ปัจจุบัน Metaverz มีมูลค่าการลงทุนในเมตาเวิร์สเกิน 100 ล้านดอลลาร์ในทรัพย์สินและสินทรัพย์ดิจิทัลต่าง ๆ และคาดว่าจะมีการเติบโตอย่างรวดเร็ว Metaverz ของ Triller จะดำเนินการ ณ จุดที่ดนตรี กีฬา การเล่นเกม และการแสดงสดซึ่งมาบรรจบกัน ผู้ใช้สามารถมีส่วนร่วมกับการแข่งขันกีฬาและดนตรีสดที่ทำลายสถิติของ Triller โดยการดึงดูดผู้ชมนับล้านทั่วโลก ซึ่งรวมถึง Bare Knuckle Fighting Championship, Triller Fight Club, Verzuz และอื่น ๆ อีกมากมาย แต่ก็ยังสามารถมีส่วนร่วมกับศิลปินและแฟน ๆ ในสภาพแวดล้อมเฉพาะตัวที่นำโลกมาสู่พวกเขา

“เมื่อการแข่งขันกีฬาที่คุณโปรดปรานซึ่งห่างออกไปเป็นทวีป แต่คุณก็ยังสามารถนั่งแถวหน้า แบ่งปันช่วงเวลาที่น่าจดจำกับแฟน ๆ คนอื่น ๆ ได้” Christopher Taurosa หัวหน้า Metaverz กล่าว “หากคุณต้องการสัมผัสประสบการณ์การช็อปปิ้งแบบดิจิทัลรูปแบบใหม่ คุณสามารถเลือกซื้อสินค้าจากร้านค้าในห้างสรรพสินค้าเสมือนจริงของเรา หรือหากคุณชื่นชอบการเล่นเกม คุณก็สามารถเล่นกับเพื่อน ๆ และโต้ตอบกับชุมชนในวิธีการมีส่วนร่วมรูปแบบใหม่ ๆ มากมายในซึ่งมีเฉพาะใน Metaverz เท่านั้น”

Metaverz เป็นตัวอย่างล่าสุดที่ว่าทำไม Triller ถึงเป็นกล่องเครื่องมือที่ทรงพลังให้แก่ครีเอเตอร์ โดยครีเอเตอร์เอง Triller ช่วยให้ครีเอเตอร์สร้างรายได้จากการเชื่อมต่ออย่างที่ไม่เคยมีมาก่อน ด้วยอัตราการมีส่วนร่วมสูงถึง 73% เทียบกับ 1% บนแพลตฟอร์มอื่น ๆ เช่นอินสตาแกรม

“Metaverz ของ Triller ตอกย้ำความมุ่งมั่นในการเพิ่มพลังให้ครีเอเตอร์จากทุกที่เพื่อเพิ่มความสัมพันธ์กับแฟน ๆ ของพวกเขา ในขณะเดียวกันก็พัฒนาเครื่องมืออันทรงพลังในการเชื่อมต่อแบรนด์และครีเอเตอร์ควบคู่ไปด้วยครับ” de Silva กล่าว “Triller กำลังทำลายแม่พิมพ์ของเครือข่ายสวนแบบปิด และ Metaverz จะยังคงปูทางให้ Triller เป็นแพลตฟอร์มครีเอเตอร์ชั้นนำ ด้วยการอำนวยความสะดวกด้านการค้าและการเข้าถึงผู้ชมสูงสุด”

เครือข่ายสวนแบบเปิดของ Triller ได้ลดความจำเป็นของบริษัทเทคโนโลยีขนาดใหญ่ด้วยการทำหน้าที่เป็นตัวกลาง และมอบอำนาจกลับคืนมาอยู่ในมือของครีเอเตอร์และผู้ใช้ ทำให้ครีเอเตอร์สามารถเชื่อมต่อกับแบรนด์ที่ต้องการทำงานร่วมกับพวกเขาได้โดยตรง

“เป้าหมายหลักของเราคือขจัดอุปสรรคในการเข้าสู่เมตาเวิร์ส แพลตฟอร์มของเราช่วยให้ทุกคนเชื่อมต่อและโต้ตอบกับครีเอเตอร์ที่พวกเขาชื่นชอบได้อย่างราบรื่น อีกทั้งยังสามารถเข้าร่วมกิจกรรมต่าง ๆ ที่ปกติไม่สามารถทำได้ และยังมีปฏิสัมพันธ์โดยตรงกับผู้คนจากทั่วโลกได้อีกด้วย” Taurosa กล่าว “Metaverz ช่วยลบข้อจำกัดของเวลาและระยะทางออกไป ทำให้สิ่งต่าง ๆ สามารถเกิดขึ้นได้ในทันที และให้พื้นที่ที่จำเป็นทั้งสองด้านของเศรษฐกิจครีเอเตอร์ในการสร้างและเพลิดเพลินกับเนื้อหาและประสบการณ์ ซึ่งคุณสามารถเป็นใครก็ได้ที่คุณอยากจะเป็นและไปในทุกที่ที่คุณต้องการ”

คุณสมบัติเฉพาะตัวอีกอย่างของประสบการณ์ Metaverz คือความร่วมมือระหว่าง Triller กับ Epik ซึ่งเป็นแพลตฟอร์มชั้นนำระดับโลกในด้าน AR/VR และประสบการณ์การเล่นเกมที่สร้างประสบการณ์ดิจิทัลระดับพรีเมียมให้กับเกมเมอร์มากกว่าหนึ่งพันล้านคนทั่วโลก Triller และ Epik จะเปิดตัวเกมหลายเกมภายใน Metaverz และประกาศความร่วมมือในอนาคตกับบริษัทเกมชั้นนำของโลกแห่งต่าง ๆ เนื่องจากการทำงานร่วมกันอย่างสร้างสรรค์นี้ ก็จะทำให้มี Metaverz ดรอป ที่นักเล่นเกมสามารถซื้อการอัปเกรดด้วยสิ่งประดิษฐ์ อุปกรณ์ และแพ็คเพิ่มเติมอย่างเช่นเทรดดิ้งการ์ดที่เป็นสิ่งประดิษฐ์หรืออวาตาร์ของตัวละครในเกม

เพื่อเฉลิมฉลองการเปิดตัวของ Metaverz Triller จะจัดงานอีเวนต์ที่มีดีเจและศิลปินอิเล็คทรอนิกส์ Sam Feldt ซึ่งจะแสดงสดจากเนเธอร์แลนด์ในช่วงงาน Amsterdam Dance Event โดยงานนี้จะเป็นอีเวนต์การรวมตัวที่ใหญ่ที่สุดในโลกงานหนึ่งในวันที่ 22 ตุลาคม อีเวนต์นี้เป็นกิจกรรมฟรีสำหรับทุกคนที่เข้าร่วมผ่านทาง Metaverz

“ผมรู้สึกตื่นเต้นมากครับที่ได้เป็นพันธมิตรกับ Triller ในการเปิดตัว Metaverz” Victor David ผู้ร่วมก่อตั้งและ CEO ของ Epik กล่าว “นี่คือการรวมตัวกันที่สมบูรณ์แบบที่ผสมผสานเครือข่ายโซเชียลของ Triller แพลตฟอร์มครีเอเตอร์ คนดัง อีเวนต์ และเนื้อหาเข้ากับความเชี่ยวชาญด้านเทคนิค เครือข่ายวิดีโอเกม และโปรแกรมสมาชิกของเรา การทำงานร่วมกันนี้ ได้ทำให้เราเข้าใกล้การนำใช้ในระดับงานสาธารณะ (mass adoption) มากขึ้นอีกก้าวหนึ่ง และผลลัพธ์ที่ได้จะเป็นการขยายไปสู่ทุกสิ่งที่เป็นเมตาเวิร์สอย่างรวดเร็ว”

Triller ซึ่งทำงานร่วมกับแบรนด์ที่ใหญ่ที่สุดในโลกหลายร้อยแบรนด์และเปิดใช้งานการโต้ตอบทางสังคมมากกว่า 750 ล้านครั้งต่อเดือน กำลังคว้าโอกาสในการสร้างรายได้จากธุรกรรมเหล่านี้ต่อไป

“เราได้ใช้ทั้งความคิด เวลา และทุนอย่างมากในการสร้างแพลตฟอร์มที่ทางเราเชื่อว่าเป็นแพลตฟอร์มเมตาเวิร์สของอีเวนต์สดที่ทันสมัยที่สุดในปัจจุบัน” de Silva กล่าว “เราได้ทำงานอย่างใกล้ชิดกับทั้งพันธมิตร ผู้มีอิทธิพล คนดัง และบริษัทของเราทั้งหมดเพื่อให้แน่ใจว่าการเปิดตัวครั้งนี้ไม่ได้มีเพียงแค่คำพูด แต่เป็นการเปิดโลกใหม่อย่างแท้จริงครับ”

ในช่วงปี 2022 เพียงปีเดียว Triller ได้ขยายการแสดงตัวตนในโลกของกีฬาต่อสู้ด้วยการเข้าซื้อกิจการของ Bare Knuckle Fight Club และ Pillow Fight Championship ในส่วนของพื้นที่สำหรับคอนเทนต์ครีเอเตอร์เอง Triller ก็ยังได้เข้าซื้อกิจการ Fangage ซึ่งเป็นแพลตฟอร์มเพื่อเพิ่มการสร้างรายได้ให้มากที่สุดแก่ครีเอเตอร์ ซึ่งเป็นการสานต่อความมุ่งมั่นของ Triller ในการให้ความสำคัญกับครีเอเตอร์เป็นอันดับแรก

สำหรับข้อมูลเพิ่มเติมและเป็นหนึ่งในคนแรก ๆ ที่จะเรียนรู้เกี่ยวกับการอัปเดตของ Metaverz กรุณาเยี่ยมชมwww.metaverz.com หรือติดตาม @triller บนโซเชียลมีเดีย @triller จะมีข้อมูลในส่วนของทีเซอร์ Metaverz.com วันที่มีการดรอป การสนับสนุนผู้มีชื่อเสียง คอนเสิร์ต อีเวนต์กีฬา ช่วงเวลาการช้อปปิ้ง และประสบการณ์การเล่นเกมที่ดียิ่งขึ้น

เกี่ยวกับ Triller 

Triller เป็นแพลตฟอร์มสวนทางเทคโนโลยีแบบเปิดที่ขับเคลื่อนโดย AI สำหรับครีเอเตอร์ จับคู่วัฒนธรรมดนตรีเข้ากับกีฬา แฟชั่น ความบันเทิง และอินฟลูเอนเซอร์ผ่านทางมุมมอง 360 องศา ของเนื้อหาและเทคโนโลยี Triller สนับสนุนให้อินฟลูเอนเซอร์โพสต์เนื้อหาที่สร้างขึ้นบนแอปผ่านแพลตฟอร์มโซเชียลมีเดียต่าง ๆ และใช้เทคโนโลยี AI ที่เป็นกรรมสิทธิ์เพื่อทำการผลักดันและติดตามเนื้อหาที่เผยแพร่ไปยังเว็บไซต์และเครือข่ายในเครือและเครือข่ายที่ไม่เกี่ยวข้อง ทำให้พวกเขาสามารถเข้าถึงผู้ใช้ได้เพิ่มขึ้นหลายล้านคน Triller ยังเป็นเจ้าของ VERZUZ ซึ่งเป็นแพลตฟอร์มดนตรีสตรีมสด; แบรนด์กีฬาการต่อสู้ทั้ง Triller Fight Club, Triad Combat และ BKFC; Amplify.ai ซึ่งเป็นแพลตฟอร์มสร้างการมีส่วนร่วมกับลูกค้าชั้นนำ;FITE.tv บริการสตรีมมิ่ง PPV, AVOD และ SVOD ชั้นนำระดับโลก; Thuzio ผู้นำในอีเวนต์และประสบการณ์ของผู้มีอิทธิพลระดับพรีเมียม B2B; Fangage แพลตฟอร์มสำหรับครีเอเตอร์เพื่อดึงดูดแฟน ๆ และสร้างรายได้จากเนื้อหา และ Julius แพลตฟอร์มสำหรับแบรนด์และเอเจนซี่เพื่อควบคุมครีเอเตอร์เพื่อการมีส่วนร่วมทางสังคมและการค้าทางสังคม

เกี่ยวกับ EpikEpik เป็นหน่วยงานออกใบอนุญาตชั้นนำระดับโลกที่นำแบรนด์ต่าง ๆ เข้ามายังวิดีโอเกมเพื่อผลิตไอเทมดิจิทัลระดับพรีเมียมและประสบการณ์สำหรับนักเล่นเกมกว่าพันล้านคนทั่วโลกด้วยระบบนิเวศดิจิทัลที่ใหญ่ที่สุด โดยมีแบรนด์ความบันเทิงยอดนิยมระดับโลกหลายร้อยแบรนด์และลูกค้าวิดีโอเกมมากกว่า 300 ราย Epik ได้รับการยอมรับอย่างกว้างขวางว่าเป็นผู้นำในอุตสาหกรรมบล็อคเชนซึ่งสร้างความร่วมมือให้แก่ของสะสมดิจิทัลที่ได้รับอนุญาตระดับพรีเมียม NFT และประสบการณ์พิเศษที่ขับเคลื่อนโดยเทคโนโลยีข้ามเชน (cross-chain) ที่เป็นกรรมสิทธิ์ซึ่งทำงานร่วมกันได้ Epik เป็นบริษัท NFT แห่งแรกและแห่งเดียวที่ทำข้อตกลงใด ๆ กับบริษัทเกม AAA สำหรับในเรื่องของ NFT ลูกค้ารายต่าง ๆ มีทั้ง ViacomCBS, Warner Music, Garena, Tencent และ Universal

ดูรายละเอียดเพิ่มเติมได้ที่ trillerinc.com

วิดีโอประกอบการประกาศนี้สามารถดูได้ที่:

https://www.globenewswire.com/NewsRoom/AttachmentNg/8c298d40-460c-4106-93da-47163adc8d8c

รูปภาพประกอบการประกาศนี้สามารถดูได้ที่:

https://www.globenewswire.com/NewsRoom/AttachmentNg/4647350d-4a3c-4d07-ae77-e23af1f3f661

https://www.globenewswire.com/NewsRoom/AttachmentNg/d68244a5-0d43-4a89-9b33-18d37e91c27f

https://www.globenewswire.com/NewsRoom/AttachmentNg/85ee27b7-f5e4-44a0-ab08-72764f562a1f

https://www.globenewswire.com/NewsRoom/AttachmentNg/3317e63d-2082-4299-98c5-6486ba44990d

https://www.globenewswire.com/NewsRoom/AttachmentNg/49cfff09-8501-48e7-ad99-6b7618793b30

https://www.globenewswire.com/NewsRoom/AttachmentNg/0f932ca7-3d31-4802-aa89-6bf36e40c15c

https://www.globenewswire.com/NewsRoom/AttachmentNg/4cb54bcc-1b80-4406-8b7d-ce4d69915c2a

https://www.globenewswire.com/NewsRoom/AttachmentNg/d73715c1-f9c4-4aa9-9d2e-90a77553e826

https://www.globenewswire.com/NewsRoom/AttachmentNg/c1b91169-93d0-4e6c-84cc-27b8def9336f

https://www.globenewswire.com/NewsRoom/AttachmentNg/64701d57-9828-483b-9fea-fcc9300b0fb0

ติดต่อ:
ฝ่ายประชาสัมพันธ์
Triller/Edendale Strategies
Curtis Vogel
Press@triller.co

QUEBEC CITY, Oct. 19, 2022 (GLOBE NEWSWIRE) — LeddarTech®, a global leader in providing the most flexible, robust and accurate ADAS and A.D. software technology, is pleased to announce its participation at two key automotive events in Detroit, Michigan where it will demonstrate LeddarVision, a unique raw data sensor fusion and perception solution that enables the mass deployment of ADAS and autonomous driving solutions.

The LeddarTech technical and management team looks forward to demonstrating its technology at these two upcoming events:

American Automotive Summit – November 1-2 – MGM Grand Detroit

The American Automotive Summit serves as an annual platform to exchange ideas surrounding the impact of market dynamics and new technologies for current and future automotive leaders. Network with over 150 of your peers, connect with exhibitors and learn from the top industry influencers and executives involved in manufacturing, operations, design, engineering, supply chain quality, and innovation.

• Presentation by Frantz Saintellemy, President and COO of LeddarTech at 12:10 EST on November 2^nd
  
  Topic: “Sensing and Perception Technology – Critical Challenges and Solutions for ADAS and AD”In this presentation, learn about the transition to software-defined vehicles and sensing and perception technology’s role in it.

• LeddarTech Booth: 9Request a meeting with LeddarTech at the event

Tech.AD USA – November 13–15 – The Henry Hotel Detroit

Tech.AD USA is the leading knowledge exchange platform in North America, bringing together 250+ stakeholders who play an active role in the vehicle automation scene.

LeddarTech Presents: LeddarVision raw data sensor fusion and perception technology

• LeddarTech Showcase Booth: 1
  Our technical experts will demonstrate how raw data fusion technology simplifies complex sensor sets and eliminates the dependency on hardware to provide customers the flexibility to scale and deliver greater ADAS and AD performance quickly.

• Live LeddarCar On-Road Demonstration Vehicle
  Limited availability- for a real-world demonstration of our one-of-a-kind software that enables Level 2-5 autonomy.Automotive Tier 1-2 suppliers and OEMs: book a LeddarCar demo

About LeddarTech

Founded in 2007, LeddarTech is an automotive ADAS and AD software company that offers comprehensive end-to-end raw data fusion and perception solutions enabling customers to solve critical challenges across the entire value chain.

LeddarTech’s automotive-grade software technology, LeddarVision, is a flexible, robust, cost-effective, sensor-agnostic solution that delivers highly accurate 3D environmental models. This scalable software supports all SAE autonomy levels by applying AI and computer vision algorithms to fuse raw data from sensors employed in L2-L5 applications. LeddarTech’s use of raw data fusion detects very small obstacles on the road with better detection rates and fewer false alarms than legacy “object fusion” solutions. In addition, unclassified obstacles are also detected, providing an additional layer of safety to the vehicle.

LeddarTech is responsible for several innovations in cutting-edge automotive and mobility applications, with over 140 patents granted or applied for, enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook and YouTube.

Contact:
Daniel Aitken, Vice-President, Global Marketing, Communications and Investor Relations, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232 daniel.aitken@leddartech.com

Investor relations contact: InvestorRelations@leddartech.com
https://investors.leddartech.com/

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, LeddarEcho, VAYADrive, VayaVision, XLRator and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/982d222e-d193-4c43-a508-d3621411c300

New cost-effective tool for monitoring diets uses data from 41 countries to show vast gaps in diets

Geneva, Oct. 18, 2022 (GLOBE NEWSWIRE) — Gallup, Harvard University, and the Global Alliance for Improved Nutrition (GAIN) have today published a new report on diet quality entitled Measuring What the World Eats. It is the first report from the Global Diet Quality Project, with data based on the Diet Quality Questionnaire (DQQ), a standard questionnaire which takes just five minutes to complete. It is a new, rapid, cost-effective method for accurately tracking data about diets and diet adequacy across the world. And the data is actionable and tailored for each country. It can be used to inform how to improve diets.

Diet is a central component of health and wellbeing. However, nearly 90% of countries experience a high level of at least two forms of malnutrition due in part to poor diets, leading to long-term health issues, including nutrient deficiencies and noncommunicable diseases. Food systems that produce our diets also have a large impact on the environment. The result is that unhealthy diets cost an estimated $3.5 trillion per year globally.

Andrew Rzepa, Gallup Partner said, “We all need better diets. But how do we make that happen? The DQQ is game changing: it gives us the detailed information we need to look at diet quality issues at a granular level, meaning we have the data to design interventions that can make a real difference. After all, we can only manage what we can measure.”

“The first step to solving a problem is describing it clearly. We knew that diets can be unhealthy in many different ways – these results put data behind it. No country, at no income level, is immune to the effects of unhealthy diets,” added Anna Herforth, principal investigator of the project at the Harvard T.H. Chan School of Public Health.

The DQQ results provide country-level data that can also be disaggregated by gender, age, urban or rural locality, and socioeconomic indicators. The data underlying this first report were collected in 41 countries, representing two thirds of the world’s population. In more than half of these countries, this was the first nationally representative dietary survey in adults ever done. The DQQ is planned to be administered to 140 countries in the future.

Key insights from the data:

• The majority of the people worldwide are not consuming diets that would even minimally adhere to dietary guidelines. This is typically worse in rural areas in low- and middle-income countries.
• Men and urban residents consume more unhealthy foods and fewer foods that protect their health. This pattern is driven by higher consumption of soft drinks, processed meats, and deep-fried foods among men than women and among urban residents than rural residents.
• Populations that consume more healthy foods also tend to consume more unhealthy foods. This means that all populations are at high risk for diet-related noncommunicable diseases.
• In many low- and middle-income countries the majority of women are not getting the diverse diets they need, increasing their risk for vitamin and mineral deficiencies and related health issues. The problem is higher in rural areas and among poorer women.

Lawrence Haddad, GAIN’s Executive Director said, “It is particularly important that we understand what is happening to diets in low- and middle-income countries in Africa and Asia. With this fast, cheap, accurate measurement tool, we can now track progress. The richness of this new data means we can work with governments, the food industry, and other NGOs to build tailored strategies to improve dietary diversity, fortification, and supplementation. This is essential to reduce undernutrition and diet-related noncommunicable diseases and their widespread consequences.”

The DQQ examined six core diet quality indicators:

1. Micronutrient adequacy
2. Food group adequacy
3. Dietary factors protective against noncommunicable diseases
4. Risk factors for noncommunicable diseases
5. Consumption of no fruits or vegetables
6. Consumption of sugar-sweetened soft drinks

Each country was given a score for each indicator.

The 41 countries included in this first report are:

Bangladesh, Benin, Bolivia, Burkina Faso, Cambodia, Cameroon, Chile, China, Colombia, Ecuador, Egypt, Gabon, Ghana, Greece, India, Indonesia, Israel, Jordan, Kazakhstan, Kenya, Laos, Lebanon, Mexico, Morocco, Mozambique, Nepal, Nicaragua, Nigeria, Pakistan, Philippines, Russia, Senegal, Sierra Leone, South Africa, Sri Lanka, Tajikistan, Tanzania, Turkey, Uganda, United States of America, and Viet Nam.

Measuring What the World Eats is available now here.

Contact Information:
Ty Beal
Research Advisor
tbeal@gainhealth.org

Edwin Shankar
Media Relations
edwin.shankar@leidar.com

This content was issued through the press release distribution service at Newswire.com.

Nyxoah to Release Third Quarter Financial Results on November 8, 2022

Mont-Saint-Guibert, Belgium – October 18, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter of 2022 on Tuesday, November 8, 2022, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

Investors interested in listening to the conference call may do so by registering for a unique personal PIN at the following link: https://register.vevent.com/register/BI0d7e0daed6e34e548b85e51146400c1a. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.nyxoah.com/events.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Attachment

• ENGLISH_Q3 2022 Earnings Call Save-the-Date_FINAL

– Internationally renowned researchers Gordon Freeman, Ph.D., Thomas Gajewski, M.D., Ph.D., Jason Luke, M.D., Ignacio Melero, M.D., Ph.D., and Anthony Tolcher, M.D., to advise Bright Peak in its mission to develop next-generation multifunctional precision immunotherapies for cancer –

SAN DIEGO & BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a privately held biotechnology company leveraging a revolutionary chemical protein engineering platform to develop next-generation multifunctional cytokine-based immunotherapies, today announced the formation of a Scientific Advisory Board (“SAB”) comprised of world-renowned experts in immuno-oncology basic, translational and clinical research.

“Bright Peak is truly privileged and excited to have such an accomplished and dedicated group of scientific and clinical experts to advise on our discovery and clinical development programs,” said Fredrik Wiklund, Chief Executive Officer of Bright Peak. “Their combined resume includes some of the most groundbreaking discoveries in immuno-oncology, from basic biology through clinical investigation.” Jon Wigginton, M.D., President of Research and Development at Bright Peak added, “We are honored to welcome this outstanding group of investigators to the Bright Peak SAB and look forward to leveraging their expertise in our shared mission to develop transformative precision immunotherapies that address significant unmet needs for patients with cancer.”

The members of Bright Peak’s Scientific Advisory Board include:

Gordon Freeman, Ph.D., Professor of Medicine at the Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, is renowned for discovering the PD-L1 and PD-L2 proteins. Dr. Freeman showed that PD-L1 and PD-L2 bound to PD-1 to turn off the immune response and that blockade of PD-L1/PD-1 enhanced immune responses. He further showed that PD-L1 is highly expressed on many tumors and allows these tumors to resist immune attack. Dr. Freeman’s work led directly to the development of a successful strategy for cancer immunotherapy – blocking the PD-1-ligand interaction. Dr. Freeman has published over 400 scientific papers and holds over 90 US patents on immunotherapies. He was elected to the National Academy of Sciences and the National Academy of Inventors, is a Fellow of the AACR and SITC Academies, and has received numerous awards, including the William B. Coley Award for Distinguished Research in Tumor Immunology, the Warren Alpert Foundation Prize, and the Richard Smalley, MD, Memorial Award. Dr. Freeman received his Ph.D. degree in Microbiology and Molecular Genetics from Harvard University.

Thomas Gajewski, M.D., Ph.D., is the AbbVie Foundation Professor in Cancer Immunotherapy, leader of the Immunology and Cancer program, and Director of Melanoma Oncology at the University of Chicago. Dr. Gajewski’s notable discoveries include the identification of the STING pathway and how it stimulates the body’s innate immune system to attack cancer, downstream pathways including Wnt/β-catenin that enable tumors to evade immune responses, and the connection between the immune system’s response to cancer and the gut microbiota. An author of more than 250 manuscripts, Dr. Gajewski is past president of SITC, a founding editor of the Journal for Immunotherapy of Cancer, past chair of the Cancer Immunopathology and Immunotherapy grant review study section at the NIH, has served on the program committees for ASCO and AACR, a grant reviewer for the Melanoma Research Alliance and Cancer Research Institute, and editor for Cancer Research. Among numerous honors, Dr. Gajewski has received the William B. Coley Award for Distinguished Research in Tumor Immunology, the ESMO award in Immuno-oncology, the American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy, and Distinguished Professor designation at the University of Chicago. He holds a B.S., Ph.D. in Immunology, and M.D. degrees from the University of Chicago where he also completed Internal Medicine Residency and Hematology/Oncology Fellowship.

Jason Luke, M.D., is the Director of the Immunotherapy and Drug Development Center at UPMC Hillman Cancer Center and Associate Professor at the University of Pittsburgh. Dr. Luke is an internationally recognized investigator in translational immuno-oncology, early phase drug development and the clinical management of cutaneous malignancies. Dr. Luke has designed and led two practice-changing studies in melanoma – the combination of anti-PD1 + low-dose anti-CTLA4 Ab in PD1 refractory disease, and establishing the role for, and FDA/EMA approval of, adjuvant anti-PD1 for stage IIB/C melanoma. More generally, Dr Luke has been a lead investigator for many first-in-human trials of novel immunotherapies and a major contributor toward the investigation of radiation, the microbiome and bioinformatic approaches in relation to cancer immunotherapy. Dr. Luke is an At Large member of the Board of Directors for SITC and has held leadership roles in SMR, AACR & ASCO. He is a member of the NCI Investigational Drug Steering Committee and the Immunotherapy Task Force co-Chair. He has received numerous awards including the Melanoma Research Foundation Humanitarian Award, ASCO Merit Award, and the NCI Cancer Clinical Investigator Team Leadership Award. Dr. Luke received an M.D. from Rosalind Franklin University of Medicine and Science/Chicago Medical School, completed Internal Medicine Residency at Boston University Medical Center and Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center.

Ignacio Melero, M.D., Ph.D., is Co-Director of the Department of Immunology and Immunotherapy and Professor of Immunology at the Clinica Universidad de Navarra and at the Center for Applied Medical Research (CIMA) of the University of Navarra, Spain. Dr. Melero is an international leader in translational tumor immunotherapy research who focuses on cytokine gene therapy, immune-stimulatory monoclonal antibodies, and cell therapy for cancer. Dr. Melero is renowned for seminal discoveries in the function of NK cell inhibitory receptors (KIRs) and T-cell co-stimulation via CD137 (4-1BB). Dr. Melero has served as principal investigator in numerous clinical trials of cancer immunotherapy and has won multiple awards including the BIAL Prize of Medicine, the Conde de Cartagena Award from the Royal Academy of Medicine, Doctor Durantez LAIR Foundation Award and a Cancer Research Institute research award. Dr. Melero earned an M.D. degree from the University of Navarra School of Medicine, completed Residency in Immunology at the Hospital Universitario de la Princesa (Madrid) and earned a Ph.D. in Immunology at La Princesa Hospital, Autonomous University of Madrid, Spain.

Anthony Tolcher, M.D., is founder and CEO of NEXT Oncology, one of the most successful and respected Phase 1 programs in oncology research. Prior to founding NEXT Oncology, Dr. Tolcher was President and Co-Founder of START LLC, one of the world’s largest Clinical Phase I and early drug development operations in cancer medicine. Dr. Tolcher is a medical oncologist with over 25 years’ experience in early drug development and clinical trials and has been involved in more than 21 of the initial Phase 1 studies of new oncology agents that subsequently were FDA approved, including PD-(L)1 inhibitors, antibody-drug conjugates, anti-tumor-associated antigen antibodies, and numerous targeted therapies, and he is currently the principal investigator of over 20 Phase 1 studies. He has over 130 peer‐reviewed publications in scientific journals and has chaired the Developmental Therapeutics Review Committee for ASCO. Dr. Tolcher obtained his M.D. degree from the University of British Columbia and then completed Internal Medicine Residency at the University of Toronto, Oncology Fellowship at the University of British Columbia and a research fellowship at the NCI, Bethesda.

About Bright Peak Therapeutics
Bright Peak is a privately held biotechnology company based in Basel, Switzerland and San Diego, CA. We are rapidly advancing a robust portfolio of next-generation, multi-functional, cytokine-based immunotherapies for the treatment of patients with cancer and autoimmune disease. We accomplish this by leveraging our world class protein engineering capabilities and our unique cell-free technology platform to chemically synthesize and conjugate novel protein therapeutics that reflect state-of-the-art insights into cytokine and immune checkpoint biology. Our pipeline stretches from discovery to IND-enabling and encompasses enhanced cytokines, antibody-cytokine conjugates and other novel formats. Bright Peak is funded by a syndicate of leading healthcare investors.

Contact:
info@brightpeaktx.com